Peter Lawson
Stock Analyst at Barclays
(1.35)
# 1,505
Out of 4,479 analysts
75
Total ratings
35.59%
Success rate
-11.52%
Average return
Main Sectors:
Top Industries:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Overweight | $13 → $17 | $9.36 | +81.62% | 3 | Jun 7, 2024 | |
| BMEA Biomea Fusion | Downgrades: Equal-Weight | $30 → $5 | $4.42 | +13.12% | 2 | Jun 7, 2024 | |
| TNGX Tango Therapeutics | Maintains: Overweight | $18 → $13 | $9.00 | +44.44% | 1 | May 24, 2024 | |
| MGNX MacroGenics | Maintains: Overweight | $25 → $14 | $4.30 | +225.58% | 6 | May 10, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Overweight | $15 | $6.40 | +134.38% | 3 | May 10, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $70 → $75 | $109.18 | -31.31% | 8 | May 3, 2024 | |
| EXEL Exelixis | Downgrades: Equal-Weight | $25 | $22.25 | +12.36% | 4 | Apr 11, 2024 | |
| TCRX TScan Therapeutics | Maintains: Overweight | $7 → $9 | $5.93 | +51.77% | 1 | Mar 7, 2024 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $60 | $25.98 | +130.95% | 5 | Feb 29, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $22 | $8.06 | +172.95% | 4 | Feb 29, 2024 | |
| SWTX SpringWorks Therapeutics | Maintains: Overweight | $47 → $63 | $38.53 | +63.51% | 3 | Feb 29, 2024 | |
| FATE Fate Therapeutics | Maintains: Overweight | $6 → $10 | $3.26 | +206.75% | 3 | Feb 27, 2024 | |
| EXAI Exscientia | Maintains: Overweight | $12 → $10 | $5.15 | +94.17% | 2 | Oct 17, 2023 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $2 → $1 | $1.05 | -4.76% | 2 | Aug 10, 2023 | |
| PRLD Prelude Therapeutics | Maintains: Equal-Weight | $7 → $5 | $3.77 | +32.63% | 4 | Aug 4, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $31 → $34 | $21.53 | +57.92% | 2 | Jul 26, 2023 | |
| NRIX Nurix Therapeutics | Initiates: Overweight | $20 | $20.91 | -4.35% | 1 | Mar 9, 2023 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $60 → $35 | $15.30 | +128.76% | 4 | Dec 21, 2022 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $80 | $36.43 | +119.60% | 1 | Nov 30, 2022 | |
| NEXI NexImmune | Maintains: Overweight | $175 → $50 | $2.58 | +1,838.74% | 2 | Aug 16, 2022 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $14 → $8 | $0.82 | +880.99% | 2 | Aug 5, 2022 | |
| BCYC Bicycle Therapeutics | Initiates: Overweight | $30 | $20.29 | +47.86% | 1 | Jul 28, 2022 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $7 → $3.5 | $1.33 | +163.16% | 3 | Jul 7, 2022 | |
| ILMN Illumina | Maintains: Underweight | n/a | $105.50 | - | 1 | Aug 6, 2021 | |
| AGIO Agios Pharmaceuticals | Upgrades: Overweight | n/a | $43.38 | - | 2 | Oct 22, 2020 | |
| XNCR Xencor | Initiates: Underweight | n/a | $19.02 | - | 1 | Mar 4, 2020 | |
| NKTR Nektar Therapeutics | Initiates: Overweight | n/a | $1.22 | - | 1 | Mar 4, 2020 | |
| EDIT Editas Medicine | Upgrades: Buy | n/a | $4.61 | - | 1 | Jan 23, 2018 | |
| CRSP CRISPR Therapeutics AG | Upgrades: Buy | n/a | $53.95 | - | 1 | Jan 23, 2018 | |
| AFMD Affimed | Initiates: Buy | $70 | $5.41 | +1,193.90% | 1 | Jul 14, 2017 |
Replimune Group
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $9.36
Upside: +81.62%
Biomea Fusion
Jun 7, 2024
Downgrades: Equal-Weight
Price Target: $30 → $5
Current: $4.42
Upside: +13.12%
Tango Therapeutics
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $9.00
Upside: +44.44%
MacroGenics
May 10, 2024
Maintains: Overweight
Price Target: $25 → $14
Current: $4.30
Upside: +225.58%
Relay Therapeutics
May 10, 2024
Upgrades: Overweight
Price Target: $15
Current: $6.40
Upside: +134.38%
Blueprint Medicines
May 3, 2024
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $109.18
Upside: -31.31%
Exelixis
Apr 11, 2024
Downgrades: Equal-Weight
Price Target: $25
Current: $22.25
Upside: +12.36%
TScan Therapeutics
Mar 7, 2024
Maintains: Overweight
Price Target: $7 → $9
Current: $5.93
Upside: +51.77%
Arvinas
Feb 29, 2024
Maintains: Overweight
Price Target: $26 → $60
Current: $25.98
Upside: +130.95%
Iovance Biotherapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $18 → $22
Current: $8.06
Upside: +172.95%
SpringWorks Therapeutics
Feb 29, 2024
Maintains: Overweight
Price Target: $47 → $63
Current: $38.53
Upside: +63.51%
Fate Therapeutics
Feb 27, 2024
Maintains: Overweight
Price Target: $6 → $10
Current: $3.26
Upside: +206.75%
Exscientia
Oct 17, 2023
Maintains: Overweight
Price Target: $12 → $10
Current: $5.15
Upside: +94.17%
Adaptimmune Therapeutics
Aug 10, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.05
Upside: -4.76%
Prelude Therapeutics
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.77
Upside: +32.63%
Syndax Pharmaceuticals
Jul 26, 2023
Maintains: Overweight
Price Target: $31 → $34
Current: $21.53
Upside: +57.92%
Nurix Therapeutics
Mar 9, 2023
Initiates: Overweight
Price Target: $20
Current: $20.91
Upside: -4.35%
Arcus Biosciences
Dec 21, 2022
Maintains: Overweight
Price Target: $60 → $35
Current: $15.30
Upside: +128.76%
Immunocore Holdings
Nov 30, 2022
Initiates: Overweight
Price Target: $80
Current: $36.43
Upside: +119.60%
NexImmune
Aug 16, 2022
Maintains: Overweight
Price Target: $175 → $50
Current: $2.58
Upside: +1,838.74%
Karyopharm Therapeutics
Aug 5, 2022
Maintains: Overweight
Price Target: $14 → $8
Current: $0.82
Upside: +880.99%
Bicycle Therapeutics
Jul 28, 2022
Initiates: Overweight
Price Target: $30
Current: $20.29
Upside: +47.86%
CytomX Therapeutics
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.33
Upside: +163.16%
Illumina
Aug 6, 2021
Maintains: Underweight
Price Target: n/a
Current: $105.50
Upside: -
Agios Pharmaceuticals
Oct 22, 2020
Upgrades: Overweight
Price Target: n/a
Current: $43.38
Upside: -
Xencor
Mar 4, 2020
Initiates: Underweight
Price Target: n/a
Current: $19.02
Upside: -
Nektar Therapeutics
Mar 4, 2020
Initiates: Overweight
Price Target: n/a
Current: $1.22
Upside: -
Editas Medicine
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $4.61
Upside: -
CRISPR Therapeutics AG
Jan 23, 2018
Upgrades: Buy
Price Target: n/a
Current: $53.95
Upside: -
Affimed
Jul 14, 2017
Initiates: Buy
Price Target: $70
Current: $5.41
Upside: +1,193.90%